Hepatitis Monthly

Published by: Kowsar

The Estimation of Economic Burden of Hepatitis B Virus Infection in Iran

Mehdi Mohammadzadeh 1 , Behnaz Fattahi 2 and Tayebeh Ghari 3 , *
Authors Information
1 Department of Pharmacoeconomy and Administrative Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 School of Pharmacy, Islamic Azad University, Tehran, Iran
3 Department of Pharmaceutics, School of pharmacy, Alborz University of Medical Sciences, Karaj, Iran
Article information
  • Hepatitis Monthly: January 01, 2017, 17 (1); e40541
  • Published Online: January 15, 2017
  • Article Type: Research Article
  • Received: July 2, 2016
  • Revised: December 25, 2016
  • Accepted: January 6, 2017
  • DOI: 10.5812/hepatmon.40541

To Cite: Mohammadzadeh M, Fattahi B, Ghari T. The Estimation of Economic Burden of Hepatitis B Virus Infection in Iran, Hepat Mon. 2017 ;17(1):e40541. doi: 10.5812/hepatmon.40541.

Abstract
Copyright © 2017, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
References
  • 1. Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol. 2000; 15(12): 1356-61[DOI][PubMed]
  • 2. Arnot R. The evolving efforts to control hepatitis B virus. Pediatr Infect Dis J. 1998; 17(7 Suppl)-9[DOI][PubMed]
  • 3. Brechot C, Jaffredo F, Lagorce D, Gerken G, Meyer zum Buschenfelde K, Papakonstontinou A, et al. Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. J Hepatol. 1998; 29(2): 173-83[DOI][PubMed]
  • 4. Kalantari HA, Jalali M. A ten-year study of histological variations of liver and laboratory findings in 100 healthy hepatitis b carriers. J Isfahan Med Sch. 2003; 67: 32-4
  • 5. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997; 337(24): 1733-45[DOI][PubMed]
  • 6. The World Bank.World Development Report 1993: Investing in Health. 2010;
  • 7. Murray CJL, Lopez. A. D. . The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. 1996;
  • 8. Murray CJ, Acharya AK. Understanding DALYs (disability-adjusted life years). J Health Econ. 1997; 16(6): 703-30[PubMed]
  • 9. Murray CJL, Salomon JA, Mathers C. A critical examination of summary measures of population health. In: Summary measures of population health: concepts, ethics, measurement, and applications. 2002;
  • 10. Kanwal F, Farid M, Martin P, Chen G, Gralnek IM, Dulai GS, et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol. 2006; 101(9): 2076-89[DOI][PubMed]
  • 11. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med. 2005; 142(10): 821-31[DOI][PubMed]
  • 12. Kavosi Z, Zare F, Jafari A, Fattahi MR. Economic burden of hepatitis B virus infection in different stages of disease; a report from southern iran. Middle East J Dig Dis. 2014; 6(3): 156-61[DOI][PubMed]
  • 13. Murray CJ, Lopez AD. Quantifying disability: data, methods and results. Bull World Health Organ. 1994; 72(3): 481-94[PubMed]
  • 14. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007; 16(4): 403-6[PubMed]
  • 15. Salehi-Vaziri M, Sadeghi F, Almasi Hashiani A, Gholami Fesharaki M, Alavian SM. Hepatitis B Virus Infection in the General Population of Iran: An Updated Systematic Review and Meta-Analysis. Hepat Mon. 2016; 16(4)[DOI][PubMed]
  • 16. Ong SC, Lim SG, Li SC. How big is the financial burden of hepatitis B to society? A cost-of-illness study of hepatitis B infection in Singapore. J Viral Hepat. 2009; 16(1): 53-63[DOI][PubMed]
  • 17. Tu HAT, Woerdenbag HJ, Riewpaiboon A, Kane S, Le DM, Postma MJ, et al. Cost of illness of chronic hepatitis b infection in vietnam. Value Health Reg Issues. 2012; 1(1): 23-8[DOI]
  • 18. Keshavarz K, Kebriaeezadeh A, Alavian SM, Akbari Sari A, Abedin Dorkoosh F, Keshvari M, et al. Economic burden of hepatitis B virus-related diseases: evidence from iran. Hepat Mon. 2015; 15(4)[DOI][PubMed]
  • 19. Kalantari H, Davari M, Akbari M, Hejazi SM, Kalantari M, Zakerin S, et al. The estimation of direct medical costs of treating patients with chronic hepatitis B and C in iran. Int J Prev Med. 2012; 3(3): 191-6[PubMed]
  • 20. Chen DS. Toward elimination and eradication of hepatitis B. J Gastroenterol Hepatol. 2010; 25(1): 19-25[DOI][PubMed]
  • 21. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006; 367(9524): 1747-57[DOI][PubMed]
  • 22. Gaunt ER, Harvala H, McIntyre C, Templeton KE, Simmonds P. Disease burden of the most commonly detected respiratory viruses in hospitalized patients calculated using the disability adjusted life year (DALY) model. J Clin Virol. 2011; 52(3): 215-21[DOI]
  • 23. Mathers CD, Vos ET, Stevenson CE, Begg SJ. The burden of disease and injury in Australia. Bull World Health Organ. 2001; 79(11): 1076-84[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments